University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 14 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tate, Deborah F
NCT05887401: Physical Activity and Healthy Eating Among Young Adult Cancer Survivors

Recruiting
N/A
100
US
Core, Simplified Nutrition Monitoring (Green), Behavioral: Simplified Nutrition Monitoring (Red), Nutrition Goals (Yes), Nutrition Goals (No), Supportive Text Messages (Yes), Supportive Text Messages (No), Lesson Delivery (Once), Lesson Delivery (Weekly)
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Physical Activity, Neoplasms, Cancer
03/25
03/25
NCT05929469: PATH to Health: An Exploration of Digital Behavioral Weight Loss Approaches

Completed
N/A
99
US
App, Fully Automated Kick-Off, Human-Enhanced Kick-Off, Check-In, Counseling
University of North Carolina, Chapel Hill, Academy of Nutrition and Dietetics
Overweight, Obesity, Overweight and Obesity
04/24
04/24
AGILE, NCT04922216: Adaptive Goals and Interventions for Lifestyle Enhancement

Completed
N/A
624
US
Core, Standard Diet Monitoring, Simplified Diet Monitoring, Adaptive Activity Goals (Daily), Adaptive Activity Goals (Weekly), Message Decision Points (Fixed), Message Decision Points (Adaptive), Message Decision Rules (Standard), Message Decision Rules (Adaptive), Message Choice (No), Message Choice (Yes)
University of North Carolina, Chapel Hill, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity
06/24
07/24
NCT06110273: Fit for Duty: mHealth Intervention for Weight Gain Prevention

Recruiting
N/A
454
US
Fit for Duty-mobile, m-Health Control
University of North Carolina, Chapel Hill, University of Virginia, National Heart, Lung, and Blood Institute (NHLBI)
Obesity
02/27
02/27
Thompson, Patrick A
NCT02945800: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Active, not recruiting
2
59
US
nab-Paclitaxel, Abraxane, Gemcitabine, Gemzar
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma
02/25
02/26
NCT04388839: Evolutionary Therapy for Rhabdomyosarcoma

Recruiting
2
28
US
Vincristine, Cyclophosphamide, Vinorelbine, Navelbine, Actinomycin D, Cosmegen, Cyclophosphamide Pill
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Rhabdomyosarcoma
08/26
08/27
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting
1/2
21
US
Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
12/24
12/25
NCT04337177: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Recruiting
1
20
US
VAL-413, Orotecan®, Temozolomide, Temodar, Temodal, Temcad, TMZ
Valent Technologies, LLC
Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
06/25
06/25
NCT01587300: Neuroblastoma Biology Study

Recruiting
N/A
1000
Canada, US
New Approaches to Neuroblastoma Therapy Consortium
Neuroblastoma
12/99
12/99
Valle, Carmina G
NCT05887401: Physical Activity and Healthy Eating Among Young Adult Cancer Survivors

Recruiting
N/A
100
US
Core, Simplified Nutrition Monitoring (Green), Behavioral: Simplified Nutrition Monitoring (Red), Nutrition Goals (Yes), Nutrition Goals (No), Supportive Text Messages (Yes), Supportive Text Messages (No), Lesson Delivery (Once), Lesson Delivery (Weekly)
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Physical Activity, Neoplasms, Cancer
03/25
03/25
AYAConnect, NCT06171945: Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors

Recruiting
N/A
60
US
AYA Connect intervention, Positive Psychology (PP) intervention, Positive Psychology Plus (PP+) intervention
UNC Lineberger Comprehensive Cancer Center
Cancer, Physical Activity, Cancer Survivorship, Mental Health, Obesity
03/25
03/25
AGILE, NCT04922216: Adaptive Goals and Interventions for Lifestyle Enhancement

Completed
N/A
624
US
Core, Standard Diet Monitoring, Simplified Diet Monitoring, Adaptive Activity Goals (Daily), Adaptive Activity Goals (Weekly), Message Decision Points (Fixed), Message Decision Points (Adaptive), Message Decision Rules (Standard), Message Decision Rules (Adaptive), Message Choice (No), Message Choice (Yes)
University of North Carolina, Chapel Hill, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity
06/24
07/24
Nudge, NCT05625061: Just-in-time Adaptive Intervention Messaging in a Digital Weight Loss Intervention for Young Adults

Active, not recruiting
N/A
206
US
Core Behavioral Weight Loss (BWL) Intervention, Behavior Change Technique 1 Message (Action Planning), Behavior Change Technique 2 Message (Discrepancy between Current Behavior and Goal), Behavior Change Technique 3 Message (Feedback on Outcome of Behavior), Behavior Change Technique 4 Message (Social Support), Behavior Change Technique 5 Message (Social Comparison), Behavior Change Technique 6 Message (Social Reward), Behavior Change Technique 7 Message (Focus on Past Success)
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Obesity, Overweight, Overweight and Obesity
01/25
03/25
Davis, Ian
P3BEP, NCT02582697 / 2015-003060-37 / ACTRN12613000496718: Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Recruiting
3
500
US, RoW
Bleomycin (active name: Bleomycin Sulfate), Blenamax (Aspen), DBL Bleomycin Sulphate (Willow Pharmaceuticals Pty Limited), Bleo Powder for injection (Hospira), Etoposide, DBL Etoposide Injection (Hospira), Etopophos (Bristol-Myers Squibb), Etoposide (Pfizer), Etoposide Ebewe (Sandoz), Cisplatin, Cisplatin Ebewe (Sandoz), Cisplatin injection (Pfizer), DBL Cisplatin Injection (Hospira), Pegylated G-CSF (Pegfilgrastim), Neulasta Syringe with Automatic Needle Guard (Amgen), Filgrastim, Neupogen (Amgen), Nivestim (Hospira), Tevagrastim (Teva Pharma Australia Pty Ltd), Zarzio (Sandoz)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cambridge University Hospitals NHS Foundation Trust, Cancer Trials Ireland, Children's Oncology Group, Dana-Farber Cancer Institute, University of Southern California
Intermediate and poor-risk metastatic germ cell tumours (GCTs)
02/22
07/23
ENZAMET, NCT02446405 / 2014-003190-42 / ACTRN12614000110684: Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

Active, not recruiting
3
1125
Europe, Canada, US, RoW
Enzalutamide, NSAA, LHRHA or Surgical Castration
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Trials Ireland, Canadian Cancer Trials Group, Astellas Pharma Inc
Prostatic Neoplasms
12/26
06/27
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
UNICAB, NCT03685448: ANZUP - Non-clear Cell Post Immunotherapy CABozantinib

Recruiting
2
48
RoW
Cabozantinib, Cabometyx
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2, Chromophobe Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Xp11.2 Translocation-Related Renal Cell Carcinoma
10/22
04/24
KEYPAD, NCT03280667: Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

Active, not recruiting
2
59
RoW
Pembrolizumab plus denosumab, Keytruda and Xgeva
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Merck Sharp & Dohme LLC, Amgen
Renal Cell Carcinoma, Clear Cell, Metastatic Kidney Cancer
06/23
06/23
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting
1/2
21
US
Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
12/24
12/25
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32

Download Options